Here, we aimed to evaluate the prognostic impact of EGFR and KRAS mutations by considering the relationship between these mutations and their histological subtype and/or tumor invasion status in resected pTis-3N0M0 lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.